The cytotoxicity of cysteinylcatechols and related compounds to human melanoma cells in vitro. 1987

I Yamada, and S Seki, and O Matsubara, and S Ito, and S Suzuki, and T Kasuga

L-3,4-Dihydroxyphenylalanine (L-dopa) and its structural analogs are known to be potently cytotoxic to melanoma cells. We examined the effects of cysteinylcatechols and related compounds, which were newly synthesized as cysteinyl derivatives of L-dopa, on the growth of human melanoma cells in vitro, and their actions were compared with those of L-dopa. 4-S- and 3-S-Cysteinylcatechols showed significantly more potent cytotoxicity to melanoma cells than did L-dopa, and 2-S-cysteinylhydroquinone was next to the catechols in potency. The mechanism of action may involve interaction with the melanocyte-specific enzyme, tyrosinase, for which the cysteinylcatechols could become a better substrate than L-dopa itself. 4-S-Cysteaminylphenol was almost comparable to L-dopa in cytotoxicity, suggesting that this phenol might be oxidized to the corresponding catechol by tyrosinase within the melanoma cells.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D010636 Phenols Benzene derivatives that include one or more hydroxyl groups attached to the ring structure.
D002396 Catechols A group of 1,2-benzenediols that contain the general formula R-C6H5O2. Pyrocatechols,o-Dihydroxybenzenes,ortho-Dihydroxybenzenes,o Dihydroxybenzenes,ortho Dihydroxybenzenes
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D003545 Cysteine A thiol-containing non-essential amino acid that is oxidized to form CYSTINE. Cysteine Hydrochloride,Half-Cystine,L-Cysteine,Zinc Cysteinate,Half Cystine,L Cysteine
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

I Yamada, and S Seki, and O Matsubara, and S Ito, and S Suzuki, and T Kasuga
August 2017, Bioorganic & medicinal chemistry,
I Yamada, and S Seki, and O Matsubara, and S Ito, and S Suzuki, and T Kasuga
January 1980, Journal of immunology (Baltimore, Md. : 1950),
I Yamada, and S Seki, and O Matsubara, and S Ito, and S Suzuki, and T Kasuga
July 1990, Journal of biochemistry,
I Yamada, and S Seki, and O Matsubara, and S Ito, and S Suzuki, and T Kasuga
May 2024, Journal of applied toxicology : JAT,
I Yamada, and S Seki, and O Matsubara, and S Ito, and S Suzuki, and T Kasuga
April 1979, The Australian journal of experimental biology and medical science,
I Yamada, and S Seki, and O Matsubara, and S Ito, and S Suzuki, and T Kasuga
January 1973, Bibliotheca haematologica,
I Yamada, and S Seki, and O Matsubara, and S Ito, and S Suzuki, and T Kasuga
October 2007, Toxicology in vitro : an international journal published in association with BIBRA,
I Yamada, and S Seki, and O Matsubara, and S Ito, and S Suzuki, and T Kasuga
January 1991, Melanoma research,
I Yamada, and S Seki, and O Matsubara, and S Ito, and S Suzuki, and T Kasuga
January 1988, Archives of toxicology,
I Yamada, and S Seki, and O Matsubara, and S Ito, and S Suzuki, and T Kasuga
January 2011, Environmental toxicology and chemistry,
Copied contents to your clipboard!